2025-09-09 - Analysis Report
Okay, here's a comprehensive analysis of TG Therapeutics (TGTX) based on the provided data, presented in English with a focus on key figures and concise interpretations.

**Report on TG Therapeutics Inc. (TGTX)**

*Company Overview:* TG Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return:**
    *   TGTX: 66.94%
    *   VOO: 101.31%
    *   Difference: -34.4%

*   **Relative Divergence:** 14.9 (Range: -110.5 to 401.1)

*Analysis:* TGTX has underperformed the S&P 500 significantly in cumulative return. The relative divergence indicates that TGTX's performance is currently near the lower end of its historical range compared to VOO.

*Alpha, Beta Analysis Table:*

| Year       | CAGR   | MDD   | Alpha    | Beta   | Cap(B) |
|------------|--------|-------|----------|--------|--------|
| 2015-2017  | -6.0%  | 56.5% | -35.0%   | -0.1   | 1.3    |
| 2016-2018  | -8.0%  | 58.6% | -26.0%   | 0.0    | 0.7    |
| 2017-2019  | 74.0%  | 58.6% | 44.0%    | 0.0    | 1.8    |
| 2018-2020  | 402.0% | 58.6% | 382.0%   | -0.4   | 8.3    |
| 2019-2021  | 125.0% | 63.5% | 76.0%    | -0.5   | 3.0    |
| 2020-2022  | -76.0% | 70.4% | -78.0%   | -0.6   | 1.9    |
| 2021-2023  | -350.0%| 70.4% | -368.0%  | -0.8   | 2.7    |
| 2022-2024  | 71.0%  | 73.1% | 45.0%    | -0.9   | 4.8    |
| 2023-2025  | 74.0%  | 73.1% | 21.0%    | 0.4    | 5.1    |

*Analysis of Alpha, Beta Table:*

*   **Volatility:** High Maximum Drawdown (MDD) values indicate significant price volatility.
*   **Alpha:** Wide range of alpha values suggest periods of both significant outperformance and underperformance compared to the market.  The negative alphas in recent years are concerning.
*   **Beta:** Beta values are generally close to zero, indicating that TGTX's price movements are relatively independent of the overall market.

**2. Recent Stock Price Movements**

*   **Current Price:** 32.21
*   **Last Market Data:**
    *   Price: 32.38
    *   Previous Close: 32.21
    *   Change: 0.53
*   **Moving Averages:**
    *   5-day: 31.31
    *   20-day: 28.85
    *   60-day: 33.57

*Analysis:* The stock price is currently above its 5-day and 20-day moving averages, but below its 60-day moving average. This suggests a recent upward trend but potential resistance around the 60-day average. The last market change indicates a slight positive movement, but not a drastic jump requiring special attention.

**3. Indicators**

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 78.84 (Overbought)
*   **PPO:** 2.48
*   **Hybrid Signal:** "cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.33)"
*   **20-day Relative Divergence Change:** +3.5 (Short-term Increase)
*   **Expected Return:** -265.9% (Compared to S&P 500)

*Analysis:*

*   **MRI:** Suggests relatively low market risk currently.
*   **RSI:** The RSI indicates the stock is currently overbought, which could signal a potential pullback or consolidation.
*   **PPO:** Positive PPO value indicates that the stock is trading above its moving average.
*   **Hybrid Signal:** The signal is giving a buy signal with caution.
*   **20-day Divergence:** The increase in relative divergence suggests the stock is outperforming its recent trend.
*   **Expected Return:** The very negative expected return is a significant concern, suggesting the model predicts substantial underperformance relative to the S&P 500 over the long term.

**4. Recent News & Significant Events**

*   **Key Headlines:**
    *   Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
    *   Another $100 Million Buyback Program Launched
    *   CEO Voices Strong Conviction In Briumvi

*Analysis:* Recent news is generally positive. The Phase 3 trial commencement is a key milestone. The buyback program and CEO's confidence signal management's belief in the company's value.

**4-2. Analyst Opinions**

*   **Consensus:**
    *   Mean Rating: Not Available (No Clear Consensus)
    *   Opinions: 6
    *   Target Price (avg/high/low): 40.50 / 53.00 / 11.00

*Analysis:* Analyst opinions are mixed, given the wide range in target prices. The absence of a clear consensus rating suggests uncertainty among analysts.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-08-08 | 0.19 | 0.14 B$    |
| 2025-05-09 | 0.03 | 0.12 B$    |
| 2024-11-07 | 0.03 | 0.08 B$    |
| 2024-08-09 | 0.05 | 0.07 B$    |
| 2025-08-08 | 0.05 | 0.07 B$    |

*Analysis:* The most recent quarter shows a significant jump in EPS and revenue, indicating potential positive momentum.

**6. Financial Information**

*Revenue and Profitability:*

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.14B  | 86.58%        |
| 2025-03-31 | $0.12B  | 87.14%        |
| 2024-12-31 | $0.11B  | 85.77%        |
| 2024-09-30 | $0.08B  | 88.86%        |
| 2024-06-30 | $0.07B  | 88.70%        |

*Capital and Profitability:*

| Quarter    | Equity  | ROE     |
|------------|---------|---------|
| 2025-06-30 | $0.28B  | 10.20%  |
| 2025-03-31 | $0.24B  | 2.13%   |
| 2024-12-31 | $0.22B  | 10.49%  |
| 2024-09-30 | $0.19B  | 2.02%   |
| 2024-06-30 | $0.18B  | 3.87%   |

*Analysis:*

*   **Revenue & Profit Margin:** Revenue is growing, and profit margins are exceptionally high, indicating strong pricing power or efficient cost management (common in biotech if a drug is selling well).
*   **Equity & ROE:**  Equity is increasing, but ROE fluctuates significantly. The most recent ROE is positive, suggesting improved profitability relative to equity.

**7. Overall Summary**

*   **Performance:** TGTX has significantly underperformed the S&P 500.
*   **Financials:** Revenue and profit margins are strong, and equity is growing.
*   **Technicals:** The stock is currently overbought, and the moving averages suggest a mixed trend.
*   **News:** Recent news is positive, driven by clinical trial progress and a buyback program.
*   **Analyst Sentiment:** Mixed analyst opinions suggest uncertainty.
*   **Key Concerns:** The very negative expected return and recent underperformance relative to the market are significant red flags. High volatility (MDD) should also be noted.

*Conclusion:* TGTX shows potential for growth based on recent financial results and news, but significant risks remain due to underperformance, volatility, and uncertain analyst sentiment. The negative expected return warrants careful consideration.
